John David Finley net worth and biography

John Finley Biography and Net Worth

CFO of Palisade Bio

Mr. Finley is an experienced financial executive having played instrumental roles in raising nearly $1 billion in capital for companies as both an internal chief financial officer (CFO) and an independent investment banker. Prior to joining Leading BioSciences as the company’s CFO, Mr. Finley was the chief executive officer, president and CFO for PointAcross, Inc., a software company providing business messaging and communications services. Mr. Finley previously co-founded Proteus Capital Partners, Inc., a firm specializing in providing financing for a variety of businesses, and was CFO at Phillips Capital, a broker/dealer firm specializing in private debt and equity capital raises. During his career, he also served as executive vice president and CFO of MetroGolf, Inc., where he successfully completed MetroGolf’s initial public offering and was instrumental in growing the start-up company to over 125 employees. Mr. Finley began his business career as a tax specialist with Deloitte & Haskins and Sells (now Deloitte LLP), and later was co-owner of Mitchell Finley & Company, a full-service accounting firm.

Mr. Finley earned a bachelor’s degree in business administration from Boise State University and a master’s degree in taxation from the University of Denver.

What is John David Finley's net worth?: The estimated net worth of John David Finley is at least $428.58 thousand as of July 7th, 2026. Mr. Finley owns 217,555 shares of Palisade Bio stock worth more than $428,583 as of July 10th. This net worth estimate does not reflect any other investments that Mr. Finley may own. Learn More about John David Finley's net worth.
How do I contact John David Finley?: The corporate mailing address for Mr. Finley and other Palisade Bio executives is 20271 Goldenrod Lane, Germantown MD, 20876. Palisade Bio can also be reached via phone at (858) 704-4900 and via email at [email protected]. Learn More on John David Finley's contact information.
Has John David Finley been buying or selling shares of Palisade Bio?: During the last quarter, John David Finley has sold $303,871.86 of Palisade Bio stock. Most recently, John David Finley sold 146,798 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $2.07, for a transaction totalling $303,871.86. Following the completion of the sale, the chief executive officer now directly owns 217,555 shares of the company's stock, valued at $450,338.85. Learn More on John David Finley's trading history.
Who are Palisade Bio's active insiders?: Palisade Bio's insider roster includes John Finley (CFO), Thomas Hallam (CEO), Mitchell Jones (Insider), Robert Trenschel (Director), and Donald Williams (Director). Learn More on Palisade Bio's active insiders.
Are insiders buying or selling shares of Palisade Bio?: During the last year, Palisade Bio insiders bought shares 4 times. They purchased a total of 80,000 shares worth more than $161,300.00. During the last year, insiders at the sold shares 4 times. They sold a total of 204,563 shares worth more than $420,524.61. The most recent insider tranaction occured on July, 7th when Director Robert Jr. Baltera bought 30,000 shares worth more than $60,900.00. Insiders at Palisade Bio own 0.1% of the company. Learn More about insider trades at Palisade Bio.
Information on this page was last updated on 7/7/2026.

John David Finley Insider Trading History at Palisade Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/7/2026	Sell	146,798	$2.07	$303,871.86	217,555
2/12/2026	Sell	3,896	$1.75	$6,818.00	27,353
5/24/2024	Buy	1,000	$4.81	$4,810.00	8,437
9/27/2023	Buy	1,000	$8.10	$8,100.00	2,892
9/13/2023	Buy	1,000	$9.90	$9,900.00	1,892
8/23/2022	Buy	490	$2.40	$1,176.00	8,616
8/16/2022	Buy	6,666	$3.75	$24,997.50	8,126
3/24/2022	Buy	500	$16.35	$8,175.00
9/21/2021	Buy	133	$36.60	$4,867.80
8/27/2021	Buy	666	$39.75	$26,473.50

John David Finley Buying and Selling Activity at Palisade Bio

Palisade Bio Company Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Today's Range

Now: $1.97

$1.90

$2.15

50 Day Range

MA: $1.92

$1.68

$2.24

2 Week Range

Now: $1.97

$0.53

$2.86

Volume

4,785,044 shs

Average Volume

4,409,775 shs

Market Capitalization

$341.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5